6-hydroxydopa

RN given refers to cpd without isomeric designation

Also Known As:

2,4,5-trihydroxyphenyl-D,L-alanine; 2,4,5-trihydroxyphenylalanine; 2,5-dihydroxytyrosine; 3,4,6-TOPA; 3,4,6-trihydroxyphenylalanine; 6-OHDOPA; 6-hydroxydopa, (D)-isomer; 6-hydroxydopa, (DL)-isomer; 6-hydroxydopa, (L)-isomer; 6-hydroxydopa, hydrochloride; 6-hydroxydopa, hydrochloride, (L)-isomer

Networked: 12 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 12/01/1992 - "Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1: implications for Parkinson's disease." 03/01/1993 - "Here we examined the ability of BDNF to confer protection on cultured dopaminergic neurons against the neurotoxic effects of 6-hydroxyDOPA (TOPA or 2,4,5-trihydroxyphenylalanine), a metabolite of the dopamine pathway suggested to participate in the pathology of Parkinson's disease. "
2.	Shock 10/06/1972 - "A significant increase in shock-induced aggression occurs in the rat 4 days after an intraventricular injection of 90 micrograms of 6-hydroxydopa. " 01/01/1981 - "Using a 15-s intershock interval, an increase in shock-induced fighting was observed following intraventricular 96 microgram 5,7-dihydroxytryptamine (5,7-DHT) and 90 microgram 6-hydroxydopa (6-OHdopa). " 01/01/1981 - "Facilitation of shock-induced fighting following intraventricular 5,7-dihydroxytryptamine and 6-hydroxydopa." 05/01/1981 - "Injections of 6-hydroxydopa and monosodium glutamate had slight effects on heat and shock responsiveness not at all comparable in degree or kind to septal lesion effects. "
3.	Melanoma (Melanoma, Malignant) 02/01/1979 - "Selective toxicity of 6-hydroxydopa for melanoma cells." 02/01/1979 - "The growth inhibitory effect of 6-hydroxydopa, a cytotoxic analog of L-dopa, was studied in melanotic and amelanotic Cloudman melanoma, mouse fibroblast L929 and Chinese hamster ovary cells. " 05/01/1985 - "We have evaluated the chemotherapeutic potential of 2,4-dihydroxyphenylalanine, a targeted prodrug that can be hydroxylated by tyrosinase (monophenol monooxygenase, EC 1.14.18.1) within melanoma cells to form the cellular toxin 2,4,5-trihydroxyphenylalanine (6-hydroxydopa). " 01/01/1985 - "A tyrosinase obtained from cultured human melanoma cells was found to oxygenate 2,4-dihydroxyphenylalanine to the strongly cytotoxic amino acid 6-hydroxydopa (2,4,5-trihydroxyphenylalanine). "
4.	Pain (Aches) 01/01/1981 - "Pain sensitivity was increased by 6-OHdopa, but both neurotoxins produced hyperreactivity to footshock. "
5.	Hypertension (High Blood Pressure) 01/01/1983 - "The extensive destruction of forebrain noradrenergic nerve terminals by the intraventricular injection of 250 micrograms of 6-hydroxydopamine prevents the subsequent development of DOCA-salt experimental hypertension in rats while the lesser destruction of noradrenergic nerve terminals produced by 90 micrograms of 6-hydroxydopa does not. "

Related Drugs and Biologics

1.	G(M1) Ganglioside
2.	Monophenol Monooxygenase (Tyrosinase)
3.	2,4-dihydroxyphenylalanine
4.	Desoxycorticosterone Acetate (DOCA)
5.	Brain-Derived Neurotrophic Factor (BDNF)
6.	Oxidopamine (6 Hydroxydopamine)
7.	5,7-Dihydroxytryptamine (5,7 Dihydroxytryptamine)
8.	Sodium Glutamate (Accent)
9.	Salts
10.	beta Adrenergic Receptors

Related Therapies and Procedures

1.	Intraventricular Injections
2.	Injections